[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526913":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":46,"collaborators":19,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":19,"eligibilityCriteria":53,"healthyVolunteers":50,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":19,"overallStatus":31,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine","EXPERIMENTAL","All subjects will be in a single arm. Patients will serve as their own control.\n\nPatients will receive general anesthesia in the usual fashion for the indicated procedures. This anesthetic will be standardized between patients. All patients participating in the study will have neuromonitoring as part of their spine surgery as standard care. Baseline motor-evoked potential data will then be collected. Then study drug Ketamine will be administered as following:\n\n* Step 1: 0.1 mg\u002Fkg bolus over 30 sec followed by infusion of 3mcg\u002Fkg\u002Fmin (0.18 mg\u002Fkg\u002Fhr)\n* Step 2: 0.3 mg\u002Fkg bolus over 30 sec followed by infusion of 15mcg\u002Fkg\u002Fmin (0.9mg\u002Fkg\u002Fhr)\n* Step 3: 0.85 mg\u002Fkg bolus over 30 sec followed by infusion at 50mcg\u002Fkg\u002Fmin (3mg\u002Fkg\u002Fhr)\n\nMotor Evoked Potentials will be collected for 5 times at minutes 2, 4, 6, 8, 10 after drug step.",[13],"Drug: Ketamine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Marc Buren, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","4154768369","marc.buren@ucsf.edu",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","San Francisco","California","94143","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-122.41942,37.77493,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":45,"phoneExt":19,"email":28},"415-514-3781",{"type":47,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100526913","phase-3-effect-of-ketamine-on-intraoperative-motor-evoked-potentials-100526913",false,"NCT06140927","Effect of Ketamine on Intraoperative Motor Evoked Potentials","Inclusion Criteria:\n\n* Adult patients (\\>18 years of age) undergoing posterior spinal fusions.\n\nExclusion Criteria:\n\n* Sensitivity or allergy to ketamine.\n* Schizophrenia or other psychotic conditions\n* Uncontrolled hypertension with systolic blood pressure greater than 180 mmHg\n* Myocardial Infarction\n* Large vascular aneurysms\n* Patients on ketamine as outpatient therapy.","ALL","18 Years","100 Years",{"count":58,"type":59},20,"ESTIMATED","INTERVENTIONAL",[62],"PHASE3","The goal of this clinical trial is to learn about the effect of ketamine on intraoperative motor evoked potentials in adult patients undergoing thoracolumbar spinal fusions. Participants will undergo a standard anesthetic. In addition to the standard anesthetic, the patients will be administered increasing doses of ketamine with motor-evoked potentials being measured at each dose, to assess any impacts.",[65,66,67],"Spine Fusion","Spine Tumor","Spinal Stenosis","2025-05-05",{"date":70,"type":71},"2025-05-07","ACTUAL",{"date":73,"type":71},"2023-12-01",{"date":75,"type":59},"2026-12-01",{"name":5,"class":6},1]